KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity

Journal of Clinical Investigation

Volumn 118, Issue 12, 2008, Pages 3990-4001

  Skoberne, Mojca ^a,d   Yewdall, Alice ^a   Bahjat, Keith S ^b,c   Godefroy, Emmanuelle ^a   Lauer, Peter ^b   Lemmens, Edward ^b   Liu, Weiqun ^b   Luckett, Will ^b   Leong, Meredith ^b   Dubensky, Thomas W ^b   Brockstedt, Dirk G ^b   Bhardwaj, Nina ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Anza Therapeutics Inc   (United States)

^c EARLE A CHILES RESEARCH INSTITUTE   (United States)

^d Cambridge Discovery Park   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; NY ESO 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LISTERIA MONOCYTOGENES; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A ANTIGENS; HUMANS; LISTERIA MONOCYTOGENES; MELANOMA; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; TH1 CELLS;

EID: 57449114574     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31350     Document Type: Article

References (53)

1. Ribas, A., Butterfield, L.H., Glaspy, J.A., and Economou, J.S. 2003. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21:2415-2432.
2. Speiser, D.E., et al. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739-746.
3. Powell, D.J., Jr., and Rosenberg, S.A. 2004. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27:36-47.
4. Rosenberg, S.A., et al. 2005. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175:6169-6176.
5. Dudley, M.E., et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346-2357.
6. Dranoff, G. 2005. CTLA-4 blockade: unveiling immune regulation. J. Clin. Oncol. 23:662-664.
7. Rosenberg, S.A., and Dudley, M.E. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 101(Suppl. 2):14639-14645.
8. O'Neill, D.W., Adams, S., and Bhardwaj, N. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 104:2235-2246.
9. Skoberne, M., and Geginat, G. 2002. Efficient in vivo presentation of Listeria monocytogenes-derived CD4 and CD8 T cell epitopes in the absence of IFN-gamma. J. Immunol. 168:1854-1860.
10. Kolb-Maurer, A., et al. 2000. Listeria monocytogenes-infected human dendritic cells: uptake and host cell response. Infect. Immun. 68:3680-3688.
11. Brockstedt, D.G., et al. 2005. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med. 11:853-860.
12. + T cells by exogenous cell-associated antigens. Immunity. 17:211-220.
13. Zammit, D.J., Cauley, L.S., Pham, Q.M., and Lefrancois, L. 2005. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity. 22:561-570.
14. Neuenhahn, M., et al. 2006. CD8alpha+ dendritic cells are required for efficient entry of Listeria monocytogenes into the spleen. Immunity. 25:619-630.
15. Brzoza, K.L., Rockel, A.B., and Hiltbold, E.M. 2004. Cytoplasmic entry of Listeria monocytogenes enhances dendritic cell maturation and T cell differentiation and function. J. Immunol. 173:2641-2651.
16. Feng, H., et al. 2005. Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J. Immunol. 175:421-432.
17. Stockinger, S., et al. 2004. IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism. J. Immunol. 173:7416-7425.
18. Fonteneau, J.F., et al. 2001. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J. Immunol. Methods. 258:111-126.
19. Mercado, R., et al. 2000. Early programming of T cell populations responding to bacterial infection. J. Immunol. 165:6833-6839.
20. Ayyoub, M., et al. 2006. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. Clin. Immunol. 118:188-194.
21. Valmori, D., et al. 2007. Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin. Immunol. 122:163-172.
22. Gnjatic, S., et al. 2006. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95:1-30.
23. Barrow, C., et al. 2006. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12:764-771.
24. Velazquez, E.F., et al. 2007. Expression of the cancer/ testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun. 7:11.
25. Adams, S., et al. 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181:776-784.
26. Muraille, E., et al. 2005. Distinct in vivo dendritic cell activation by live versus killed Listeria monocytogenes. Eur. J. Immunol. 35:1463-1471.
27. O'Neill, D., and Bhardwaj, N. 2005. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol. Med. 109:1-18.
28. Dillman, R.O., Selvan, S.R., and Schiltz, P.M. 2006. Patient-specific dendritic-cell vaccines for metastatic melanoma. N. Engl. J. Med. 355:1179-1181.
29. Li, Z., Zhao, X., Higgins, D.E., and Frankel, F.R. 2005. Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity. Infect. Immun. 73:5065-5073.
30. Gunn, G.R., et al. 2001. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167:6471-6479.
31. Brockstedt, D.G., et al. 2004. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. U. S. A. 101:13832-13837.
32. Singh, R., Dominiecki, M.E., Jaffee, E.M., and Paterson, Y. 2005. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 175:3663-3673.
33. Bruhn, K.W., Craft, N., Nguyen, B.D., Yip, J., and Miller, J.F. 2005. Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. Vaccine. 23:4263-4272.
34. Starks, H., et al. 2004. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 173:420-427.
35. Angelakopoulos, H., et al. 2002. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70:3592-3601.
36. Bahjat, K.S., et al. 2006. Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect. Immun. 74:6387-6397.
37. Lauvau, G., et al. 2001. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science. 294:1735-1739.
38. Datta, S.K., et al. 2006. Vaccination with irradiated Listeria induces protective T cell immunity. Immunity. 25:143-152.
39. Schoen, C., et al. 2005. Bacterial delivery of functional messenger RNA to mammalian cells. Cell. Microbiol. 7:709-724.
40. Edelson, B.T., and Unanue, E.R. 2002. MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J. Immunol. 169:3869-3875.
41. Torres, D., et al. 2004. Toll-like receptor 2 is required for optimal control of Listeria monocytogenes infection. Infect. Immun. 72:2131-2139.
42. O'Connell, R.M., et al. 2005. Immune activation of type I IFNs by Listeria monocytogenes occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TNFR-associated NF kappa B kinase-binding kinase 1. J. Immunol. 174:1602-1607.
43. Janssen, E.M., et al. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421:852-856.
44. Shedlock, D.J., and Shen, H. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:337-339.
45. Williams, M.A., Tyznik, A.J., and Bevan, M.J. 2006. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 441:890-893.
46. Lauer, P., Chow, M.Y., Loessner, M.J., Portnoy, D.A., and Calendar, R. 2002. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J. Bacteriol. 184:4177-4186.
47. Godefroy, E., et al. 2006. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin. Immunol. 121:54-62.
48. Montes, M., et al. 2005. Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin. Exp. Immunol. 142:292-302.
49. Lee, A.W., et al. 2002. A clinical grade cocktail of cytokines and PGE(2) results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 20(Suppl. 4):A8-A22.
50. Fonteneau, J.F., et al. 2001. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J. Immunol. Methods. 258:111-126.
51. Altman, J.D., et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.
52. Fonteneau, J.F., et al. 2003. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood. 101:3520-3526.
53. Lutz, M.B., et al. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods. 223:77-92.